Trevi Therapeutics, Inc. Operating Income
Trevi Therapeutics, Inc. (TRVI) reported Operating Income of -$20.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Trevi Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$20.51M.
- Trevi Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$14.91M.
- Trevi Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$10.22M.
- Trevi Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$13.92M.
- Trevi Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$49.33M.
- Trevi Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$51.52M.
- Trevi Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$33.92M.
- Trevi Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$29.91M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.51M 10-Q · filed 2026-08-06 | -$35.42M 10-Q · filed 2026-08-06 | -$45.64M derived: sum of 3 quarters · filed 2026-08-06 | -$59.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$14.91M 10-Q · filed 2026-05-05 | -$25.13M derived: sum of 2 quarters · filed 2026-05-05 | -$39.05M derived: sum of 3 quarters · filed 2026-05-05 | -$52.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$10.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$24.14M derived: sum of 2 quarters · filed 2026-03-17 | -$37.86M derived: sum of 3 quarters · filed 2026-08-06 | -$49.33M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$13.92M 10-Q · filed 2025-11-13 | -$27.64M derived: sum of 2 quarters · filed 2026-08-06 | -$39.11M 10-Q · filed 2025-11-13 | -$51.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$13.72M 10-Q · filed 2026-08-06 | -$25.19M 10-Q · filed 2026-08-06 | -$37.44M derived: sum of 3 quarters · filed 2026-08-06 | -$51.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$11.47M 10-Q · filed 2026-05-05 | -$23.71M derived: sum of 2 quarters · filed 2026-05-05 | -$37.80M derived: sum of 3 quarters · filed 2026-05-05 | -$51.09M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$12.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$26.33M derived: sum of 2 quarters · filed 2026-03-17 | -$39.62M derived: sum of 3 quarters · filed 2026-03-17 | -$51.52M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$14.09M 10-Q · filed 2025-11-13 | -$27.38M derived: sum of 2 quarters · filed 2025-11-13 | -$39.28M 10-Q · filed 2025-11-13 | -$48.22M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$13.29M 10-Q · filed 2025-08-07 | -$25.20M 10-Q · filed 2025-08-07 | -$34.13M derived: sum of 3 quarters · filed 2025-08-07 | -$43.17M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$11.91M 10-Q · filed 2025-05-08 | -$20.84M derived: sum of 2 quarters · filed 2025-05-08 | -$29.88M derived: sum of 3 quarters · filed 2025-05-08 | -$38.27M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$8.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$17.98M derived: sum of 2 quarters · filed 2025-03-18 | -$26.36M derived: sum of 3 quarters · filed 2025-03-18 | -$33.92M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$9.04M 10-Q · filed 2024-11-06 | -$17.43M derived: sum of 2 quarters · filed 2024-11-06 | -$24.99M 10-Q · filed 2024-11-06 | -$31.65M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$8.38M 10-Q · filed 2024-08-08 | -$15.95M 10-Q · filed 2024-08-08 | -$22.60M derived: sum of 3 quarters · filed 2024-08-08 | -$31.01M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$7.56M 10-Q · filed 2024-05-07 | -$14.22M derived: sum of 2 quarters · filed 2024-05-07 | -$22.63M derived: sum of 3 quarters · filed 2024-05-07 | -$30.45M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$6.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$15.06M derived: sum of 2 quarters · filed 2024-03-20 | -$22.88M derived: sum of 3 quarters · filed 2024-03-20 | -$29.91M 10-K · filed 2024-03-20 |
| 2022-09-30 | -$8.40M 10-Q · filed 2023-11-09 | -$16.23M derived: sum of 2 quarters · filed 2023-11-09 | -$23.25M 10-Q · filed 2023-11-09 | -$31.52M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$7.82M 10-Q · filed 2023-08-10 | -$14.85M 10-Q · filed 2023-08-10 | -$23.12M derived: sum of 3 quarters · filed 2023-08-10 | -$30.07M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$7.03M 10-Q · filed 2023-05-11 | -$15.30M derived: sum of 2 quarters · filed 2023-05-11 | -$22.25M derived: sum of 3 quarters · filed 2023-05-11 | -$31.41M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$15.22M derived: sum of 2 quarters · filed 2023-03-16 | -$24.39M derived: sum of 3 quarters · filed 2023-03-16 | -$32.48M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$6.95M 10-Q · filed 2022-11-10 | -$16.11M derived: sum of 2 quarters · filed 2022-11-10 | -$24.20M 10-Q · filed 2022-11-10 | -$33.40M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$9.17M 10-Q · filed 2022-08-11 | -$17.26M 10-Q · filed 2022-08-11 | -$26.45M derived: sum of 3 quarters · filed 2022-08-11 | -$33.69M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$8.09M 10-Q · filed 2022-05-12 | -$17.28M derived: sum of 2 quarters · filed 2022-05-12 | -$24.53M derived: sum of 3 quarters · filed 2022-05-12 | -$31.94M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$16.44M derived: sum of 2 quarters · filed 2022-03-17 | -$23.85M derived: sum of 3 quarters · filed 2022-03-17 | -$32.49M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$7.24M 10-Q · filed 2021-11-10 | -$14.66M derived: sum of 2 quarters · filed 2021-11-10 | -$23.30M 10-Q · filed 2021-11-10 | -$30.06M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$7.41M 10-Q · filed 2021-08-12 | -$16.05M 10-Q · filed 2021-08-12 | -$22.82M derived: sum of 3 quarters · filed 2021-08-12 | -$30.47M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$8.64M 10-Q · filed 2021-05-13 | -$15.40M derived: sum of 2 quarters · filed 2021-05-13 | -$23.05M derived: sum of 3 quarters · filed 2021-05-13 | -$30.47M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$14.42M derived: sum of 2 quarters · filed 2021-03-25 | -$21.83M derived: sum of 3 quarters · filed 2021-03-25 | -$26.64M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$7.65M 10-Q · filed 2020-11-12 | -$15.07M derived: sum of 2 quarters · filed 2020-11-12 | -$19.88M 10-Q · filed 2020-11-12 | -$25.81M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$7.42M 10-Q · filed 2020-08-13 | -$12.23M 10-Q · filed 2020-08-13 | -$18.16M derived: sum of 3 quarters · filed 2020-08-13 | -$23.11M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | -$4.81M 10-Q · filed 2020-05-07 | -$10.74M derived: sum of 2 quarters · filed 2020-05-07 | -$15.70M derived: sum of 3 quarters · filed 2020-05-07 | -$20.08M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$10.89M derived: sum of 2 quarters · filed 2020-03-16 | -$15.27M derived: sum of 3 quarters · filed 2020-03-16 | -$18.41M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$4.96M 10-Q · filed 2019-11-14 | -$9.34M derived: sum of 2 quarters · filed 2019-11-14 | -$12.48M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$4.38M 10-Q · filed 2019-08-12 | -$7.52M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$3.14M 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |